Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
COO · against 157 other Healthcare companies of similar size
Ranked #41 of 158 · scores higher than 75% of peers
Bars: peers in each 10-point band of the valuation score18 peers with a valuation score of 70–79, including COO · Click a bar to see the companies
Mainly thanks to its free cash flow yield, earnings yield and EBITDA yield, which are stronger than most Healthcare peers.
| Metric | COO | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 156 reported | 4.8% | 2.6% | 83% | 30% | |
| EBITDA yieldHigher is better · 158 reported | 6.6% | 4.8% | 66% | 50% | |
| Free cash flow yieldHigher is better · 92 reported | 5.9% | 2.5% | 84% | 20% | |
| Book yieldHigher is better · 156 reported | 72.0% | 19.6% | 95% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 52.2B HKD (≈$6.7B) | 99 | 56 | |
| 2 | 89.5B HKD (≈$11.5B) | 98 | 67 | |
| 3 | 10.4B USD | 96 | 64 | |
| 4 | 80.2B CNY (≈$11.2B) | 95 | 76 | |
| 4 | 21.5B USD | 95 | 60 | |
| 36 | 1.17T JPY (≈$8.0B) | 71 | 58 | |
| 36 | 975.0B INR (≈$11.7B) | 71 | 65 | |
| 36 | 14.9B EUR (≈$16.4B) | 71 | 52 | |
| 36 | 10.9B EUR (≈$11.9B) | 71 | 59 | |
| 41 | 11.6B USD | 70 | 56 | |
| 42 | 9.0B USD | 69 | 57 | |
| 42 | 9.2B USD | 69 | 47 | |
| 42 | 101.7B BRL (≈$18.3B) | 69 | 58 | |
| 42 | 5.2B CHF (≈$5.9B) | 69 | 69 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score